Cellares Corporation, a South San Francisco, Calif.-based life sciences technology company that automates cell therapy manufacturing, secured $82m in Series B round, bringing total funding to date to $100m.
The round was led by new investor Decheng Capital with participation from existing investor Eclipse Ventures and 8VC and new backer Skyviews Life Science.
The company intends to use the funds to accelerate development of the Cell Shuttle.
Led by Fabian Gerlinghaus, co-founder and CEO, Cellares is advancing the Cell Shuttle, which enables end-to-end automation of the process of creating highly-individualized cell therapies, including CAR-T therapies currently used to treat blood cancers by modifying and growing cells from the patient’s own immune system to attack cancer cells. The platform allows pre-clinical development to transfer to the clinical environment – saving years compared with traditional manufacturing methods – and enables quick and efficient commercial scalability. The Cell Shuttle is a modular and automated solution comprising hardware, software, robotics and consumables and it is capable of producing 10 patient doses simultaneously.